BK0414 Monoclonal Antibody Concept
- 853.906
- +3.279+0.39%
Hengrui diet pills went overseas for 6 billion US dollars, and this time they are no longer making wedding gowns for others | Insight Research
Through an innovative transaction structure, Hengrui uses minimal risk to obtain the highest potential overseas returns, while providing shareholders with more stable returns.
2024 Financial Report | After breaking through 40 billion dollars in revenue, how can Huadong Pharmaceutical face the challenge of “deceleration”
Big dividends
2024 Financial Report | Profit growth hit its lowest level in 10 years. Is Changchun Gaoxin's growth hormone ceiling here?
The time for the “first strain of growth hormone” to slow down has arrived. On March 20, Changchun Hi-Tech (000661.SZ) released its 2023 financial report, showing that current revenue and net profit to mother were 14.566 billion yuan and 4.532 billion yuan respectively, up 15.35% and 9.47% year-on-year respectively. This net profit growth rate to mother hit a record low since 2014. On March 20, Changchun Hi-Tech closed down 2.57%. Specifically, the current revenue and net revenue of Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as “Jinsai Pharmaceutical”), the core subsidiary responsible for growth hormone under Changchun Hi-Tech
Backed by Huadong Pharmaceutical, Quanxin Biotech's All in the Field of Self-Immunity | Insight Research
Through a hearing on the Hong Kong Stock Exchange, the secondary market also welcomed a major free player.
Huahai Pharmaceutical's refinancing bets on 100 tons of COVID-19 drugs: disputes over economic benefits still exist
In the context of tightening refinancing, the rationality and necessity of refinancing for A-share companies has received widespread attention from the market. Recently, Huahai Pharmaceutical (600521.SH) updated the refinancing inquiry response materials. Among them, the issue of the rationality of estimating the economic benefits of the production expansion plan attracted the attention of the regulatory authorities. According to the application materials, Huahai Pharmaceutical plans to raise 1,560 billion yuan to invest in the construction of “digital intelligent manufacturing of formulations”, “multi-functional production platform for specialty APIs such as antiviruses” projects, and supplementary liquidity. Among them, the “Multifunctional Production Platform for Antiviral and Other Special APIs” project involves “an annual output of 100 tons
Shanghai Fosun Pharmaceutical Reports 1H Results
Shanghai Pharmaceuticals Holding Co., Ltd Goes Ex Dividend on Monday
Ardelyx Announces Acceptance Of New Drug Application For Tenapanor For Hyperphosphatemia In China; Triggers $2M Milestone Payment To Ardelyx Under The Terms Of The License Agreement Between Co And Shanghai Fosun Pharmaceutical Industrial Development Co.
Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, t
The FDA Clears C4 Therapeutics' Investigational New Drug Application For CFT8919 For Non-small Cell Lung Cancer; C4T Expects To Initiate Trials Outside Greater China After Betta Pharmaceuticals Concludes Phase 1 Dose Escalation Study In Greater China
The FDA Clears C4 Therapeutics' Investigational New Drug Application For CFT8919 For Non-small Cell Lung Cancer; C4T Expects To Initiate Trials Outside Greater China After Betta Pharmaceuticals Conclu
Disc Medicine Announces Exclusive Licensing Agreement With Mabwell Therapeutics For Novel Anti-TMPRSS6 Monoclonal Antibodies To Modulate Iron Homeostasis; Mabwell To Receive $10M Upfront Payment And Up To $412.5M In Milestones
Disc Medicine Announces Exclusive Licensing Agreement With Mabwell Therapeutics For Novel Anti-TMPRSS6 Monoclonal Antibodies To Modulate Iron Homeostasis; Mabwell To Receive $10M Upfront Payment And U
China's National Medical Products Administration In Late December Met With Several Chinese Drugmakers Including Zhejiang Huahai Pharmaceutical And CSPC Pharmaceutical Group To Discuss Preparations Needed To Make A Generic Version Of Paxlovid
China's National Medical Products Administration In Late December Met With Several Chinese Drugmakers Including Zhejiang Huahai Pharmaceutical And CSPC Pharmaceutical Group To Discuss Preparations Nee
INNOVATE Corp's MediBeacon Receives $10M In Amended Agreements With Huadong Medicine
MediBeacon Inc., a portfolio company within the Pansend Life Sciences segment of INNOVATE Corp. (NYSE:VATE), today announced amendments to its commercial partnership with Huadong Medicine Co., Ltd., w
Healthcare Stocks Rally Last Month as Investors Look For Safe Bets
Healthcare stocks ended with their best monthly performance since April 2020 as investors looked for shelter amid the rate-hiking cycle and weaker economic outlook.
Today's Pre-Market Stock Movers: PEP, MRNA, BGNE, CCJ and More
Moderna & Merck (MRK) announce exercise of option by Merck for joint development and commercialization of investigational personalized cancer vaccine)
Market Chatter: Fosun Pharma in Talks With Beijing Over Pfizer-BioNTech's COVID-19 Vaccine; Shares Fall 4%
11:53 PM EDT, 03/24/2022 (MT Newswires) -- Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) and the Chinese government are still discussing the approval for the use of Pfizer and BioNTech's COVID-
Shanghai Fosun Pharmaceutical reports FY results
Shanghai Fosun Pharmaceutical press release (OTCPK:SFOSF): FY net profit attributable to shareholders of the listed company amounted to RMB 4,735M, representing an increase of 29.28% Y/Y.The net prof
Yum China, Four Others Face Delisting Risk in US Over Auditing Violations
10:19 PM EDT, 03/13/2022 (MT Newswires) -- Yum China Holdings (HKG:9987) and four other Chinese companies listed in the US are at risk of being delisted from New York bourses after the US Securities a
Market Chatter: SoftBank, Others in Talks to Raise Up to $300 Million For Chinese Vaccine Maker Suzhou Abogen
09:26 PM EST, 11/28/2021 (MT Newswires) -- Softbank Group (TYO:9984) and other investors are in final-stage talks with Chinese mRNA vaccine maker Suzhou Abogen Biosciences for a $300 million to $400
Fosun Pharma Forms Two Funds to Invest in New Drug-Related Projects
04:09 AM EST, 11/25/2021 (MT Newswires) -- Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) formed two investment funds in a bid to invest in early-stage innovative drug projects relating to non-
CStone Pharma Grants Jiangsu Hengrui Rights to Investigational Cancer Drug in Greater China
07:49 PM EST, 11/21/2021 (MT Newswires) -- CStone Pharmaceuticals (HKG:2616) granted Jiangsu Hengrui Pharmaceuticals (SHA:600276) an exclusive license to its CS1002 antibody, which is under clinical